mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 996-1004

  Cortez, Maria A A ^a   Scrideli, Carlos A ^a   Yunes, José A ^b   Valera, Elvis T ^a   Toledo, Sílvia R C ^c   Pavoni Ferreira, Patrícia C B ^c   Lee, Maria L M ^c   Petrilli, Antônio S ^c   Brandalise, Silvia R ^b,d   Tone, Luiz G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTRO INFANTIL BOLDRINI   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Acute lymphoblastic leukemia; Cancer biology; Multidrug resistance

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BREAST CANCER RESISTANCE PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MERCAPTOPURINE; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; TIOGUANINE; VINCRISTINE;

ABCB1 GENE; ABCC1 GENE; ABCC3 GENE; ABCG2 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLEEDING DISORDER; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DEATH; EVENT FREE SURVIVAL; FEMALE; GENE; GENE EXPRESSION; HEMOPHAGOCYTIC SYNDROME; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LRP GENE; MAJOR CLINICAL STUDY; MALE; MVP GENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK; SAMPLE; SEPSIS; TREATMENT FAILURE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION PROFILING; GENES, MDR; HUMANS; INFANT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK ASSESSMENT; RNA, MESSENGER; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 71049164788     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22220     Document Type: Article

References (54)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-615.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
3. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998;91:2092-2098. (Pubitemid 28185513)
4. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-627.
5. Swerts K, De Moerloose B, Dhooge C, et al. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 2006;42:295-309. (Pubitemid 43132884)
6. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood 1999;94:1086-1099.
7. Fujimaki S, Funato T, Harigae H, et al. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 2002;48:811-817. (Pubitemid 34587579)
8. McLornan DP, McMullin MF, Johnston P, et al. Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opin Drug Metab Toxicol 2007;3:363-377. (Pubitemid 47316029)
9. Weisburg JH. Multidrug resistance in acute myeloid leukemia: Potential new therapeutics. J Nucl Med 2008;49:1405-1407.
10. Glavinas H, Krajcsi P, Cserepes J, et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004;1:27-42.
11. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234.
12. Scrideli CA, Assumpção JG, Ganazza MA, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 2009;94:781-789.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
14. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706. (Pubitemid 29126745)
15. Steinbach D, Furchtbar S, Sell W, et al. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia 2003;17: 470-471. (Pubitemid 36266929)
16. Valera ET, Scrideli CA, Queiroz RG, et al. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 2004;122:166-171.
17. Plasschaert SL, de Bont ES, Boezen M, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005;11:8661-8668. (Pubitemid 43005914)
18. Efferth T, Gillet JP, Sauerbrey A, et al. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2006;5:1986-1994. (Pubitemid 44336570)
19. Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 2000;3: 268-280.
20. Taniguchi S, Mochida Y, Uchiumi T, et al. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther 2003;2:1351-1359.
21. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004;43:553-576. (Pubitemid 38951800)
22. Erdelyi DJ, Kamory E, Zalka A, et al. The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia. Cell Immunol 2006;244:121-124. (Pubitemid 46733913)
23. Gradhand U, Tegude H, Burk O, et al. Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene. Life Sci 2007;80:1490-1494. (Pubitemid 46399747)
24. Cervenak J, Andrikovics H, Ozvegy-Laczka C, et al. The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett 2006;234:62-72. (Pubitemid 43348491)
25. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006;112:457-473. (Pubitemid 44486412)
26. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 2007;26:183-201. (Pubitemid 46452190)
27. Pieters R, Kaspers GJ, van Wering ER, et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993;7:392-397. (Pubitemid 23093097)
28. Kaspers GJ, Pieters R, Van Zantwijk CH, et al. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 1995;19: 407-416.
29. Olson DP, Taylor BJ, La M, et al. The prognostic significance of Pglycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: A retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymphoma 2005;46:681-691.
30. Schneider E, Cowan KH, Bader H, et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995;85:186-193.
31. Legrand O, Perrot JY, Tang R, et al. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol 1996;94:23-33. (Pubitemid 26232535)
32. Steinbach D, Wittig S, Cario G, et al. The multidrug resistance- associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 2003;102:4493-4498. (Pubitemid 37494115)
33. Ikeda K, Oka M, Yamada Y, et al. Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance- protein (LRP) genes. Intern J Cancer 1999;82:599-604. (Pubitemid 29343463)
34. Yasunami T,Wang YH, Tsuji K, et al. Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leuk Res 2007;31: 465-470. (Pubitemid 46198945)
35. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: Was P-gp nothing but the first head of the Hydra? Leukemia 2007;21:1172-1176.
36. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000;85:711-721. (Pubitemid 30617105)
37. Kanerva J, Tiirikainen MI, Makipernaa A, et al. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: No evidence of prognostic impact in follow-up. Pediatr Hematol Oncol 2001;18:27-36.
38. Casale F, D'Angelo V, Addeo R, et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep 2004;12: 1201-1207.
39. Dhooge C, De Moerloose B, Laureys G, et al. Expression of the multidrug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: Results of a long-term prospective study. Leuk Lymphoma 2002; 43:309-314. (Pubitemid 34202109)
40. Sauerbrey A, Voigt A, Wittig S, et al. Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma 2002;43:875-879. (Pubitemid 34428677)
41. Ogretmen B, Barredo JC, Safa AR. Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2000;22:45-49. (Pubitemid 32266837)
42. Sauerbrey A, Sell W, Steinbach D, et al. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukemia. Br J Haematol 2002;118:147-150. (Pubitemid 34779530)
43. Beck WT, Grogan TM, Willman CL, et al. Methods to detect Pglycoprotein- associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 1996;56:3010-3020.
44. Broxterman HJ, Lankelma J, Pinedo HM, et al. Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 1997;11:1110-1118. (Pubitemid 27345964)
45. Marie JP, Huet S, Faussat AM, et al. Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris. Leukemia 1997;11:1086-1094. (Pubitemid 27345961)
46. Pall G, Spitaler M, Hofmann J, et al. Multidrug resistance in acute leukemia: A comparison of different diagnostic methods. Leukemia 1997;11:1067-1072. (Pubitemid 27345958)
47. Pallis M, Fisher J, Truran L, et al. Reproducible measurements of AML blast p-glycoprotein function in 2 center analyses. Blood 2005;105:1367-1368. (Pubitemid 40170918)
48. Ross DD, Karp JE, Chen TT, et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000;96:365-368.
49. van der Kolk DM, de Vries EG, Muller M, et al. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 2002; 43:685-701. (Pubitemid 34428655)
50. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-237.
51. Ceckova M, Vackova Z, Radilova H, et al. Effect of ABCG2 on cytotoxicity of platinum drugs: Interference of EGFP. Toxicol In Vitro 2008;22:1846-1852.
52. Vlaming ML, Pala Z, van Esch A, et al. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 2008;14:8152-8160.
53. Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008;35:572-579.
54. Weiss JR, Baer MR, Ambrosone CB, et al. Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2007;16:1038-1041.